We envision personalized, efficient and clinically smart cardiac care that helps drive optimal outcomes throughout the patient journey. Our vision offers strategic and focused approach, addressing critical cardiac care needs and meeting better health outcomes, lower cost of care and improved patient and staff experience.
That’s why the Philips Interventional Applications Platform — IntraSight Mobile offers a comprehensive suite of clinically proven1-5 imaging and physiology tools on a modern, secure platform.
Providing versatility, IntraSight can now be experienced on an easy to maneuver mobile cart for all environments. Ideally suited for acute and non-acute settings. Customize your platform, select the best-in-class imaging and physiology tools that are right for your coronary or peripheral vascular patients. Seamless mobile integration with any interventional suite enabling the use of Philips interventional precision tools.
*Product availability is subject to country regulatory clearance. Please contact your local sales representative to check availability in your country.
For customers with non-Philips interventional suites, IntraSight 7 offers seamless integration and full use of our interventional applications. IntraSight 7 promotes enhanced workflow management with the tableside touch screen module allowing for ease of use and access to best in class interventional tools such as iFR/FFR, IVUS and co-registration. Additionally, IntraSight 7 integration with non-Philips interventional suites allows customers to benefit from intuitive solutions such as, vessel enhancement and device detection, ultimately allowing all customers to benefit from IntraSight 7’s comprehensive offering of smart solutions without compromise.
IntraSight 7, iFR Co-registration and IVUS Co-registration are not available on IntraSight mobile platform.
Stay up-to-date and get informed about interventional cardiology topics. Or get in touch with our sales team.
the gold standard among resting indices, 1,2,7 whichis included in both the AUC (ACC Appropriate UseCriteria)8 and NCDR (National Cardiovascular Data Registry)9 and received a Class IA ESC (EuropeanSociety of Cardiology) guideline10
with the angiogram using iFR Co-registration, IVUS Co-registration and Tri-registration features6
to be run tableside without breaking scrub with the touch screen module
Built on a smart, applications-based platform that can scale to meet the evolving needs of your lab when new applications or modalities become available, without the need to purchase new hardware. Only Philips Interventional Applications Platform - IntraSight,6 offers best-in-class imaging and physiology tools with iFR, iFR Co-registration, FFR, IVUS, IVUS Co-registration, and Angio+. With its modular architecture, IntraSight stays on top of latest advances and important security updates.
the gold standard among resting indices because it’s backed by patient outcomes, that reduces costs, procedural time and patient discomfort1-3 while providing advance guidance with co-registration. With iFR Co-registration there is no need for hyperemic drugs and no need for guesswork.
is “definitely beneficial” for patients,11 and resulted in a change of treatment plans 74% of the time.12
First interventional platform to run on Microsoft Windows 10, providing the latest data encryption and advanced protection against cybersecurity threats. Usernames/passwords controlled by administrator and system auto logout safter timeout.
Delivering an outstanding user experience with a modern, intuitive interface that minimizes learning curves and increases workflow confidence.
Easy-to-use because you can:
Video 1
Video 2
Optimizing lab performance with tableside touchscreen control, systems integration, data management and remote service diagnostics
Increase case efficiency, save time and reduce errors with seamless data
Image 1
Image 2
The IntraSight applications platform is where imaging, physiology, co-registration* and software all come together to clearly identify coronary and peripheral artery disease, and allow for more optimized treatment plans. IntraSight is built on a new foundational platform designed to meet the evolving needs of your lab today and tomorrow.
IntraSight Mobile is an easy-to-use, small footprint, digital IVUS imaging and physiology system, designed for peripheral vascular and coronary procedures, operable directly from the sterile field. This is available for the hospital, office-based lab, and ambulatory surgery center environment.
Product availability is subject to country regulatory clearance. Please contact your local sales representative to check availability in your country. 1. Davies JE, et al., DEFINE-FLAIR: A Multi- Centre, Prospective, International, Randomized, Blinded Comparison of Clinical Outcomes and Cost Efficiencies of iFR andFFR Decision-Making for Physiological Guided Coronary Revascularization. New England Journal of Medicine, epub March 18, 2017. 2. Gotberg M, et al., iFR-SWEDEHEART Investigators.. Instantaneous Wave-free Ratio versus Fractional Flow Reserve to Guide PCI. N Engl J Med. 2017 May 11;376(19):1813-18233. 3. Patel M. “Cost-effectiveness of instantaneous wave-Free Ratio (iFR) compared with Fractional Flow Reserve (FFR) to guide coronary revascularization decision-making.” Late-breaking Clinical Trial presentation at ACC on March 10, 2018. 4. A. Maehara, M. Matsumura, Z.A. Ali, G.S. Mintz, G.W. Stone. IVUS-guided versus OCT-guided coronary stent implantation. J Am Coll Cardiol Img, 10 (2017), pp. 1487-1503. 5. Choi K, et al. Impact of Intravascular Ultrasound-Guided Percutaneous Coronary Intervention on Long-Term Clinical Outcomes in Patients Undergoing ComplexProcedures. JACC: Cardiovascular Interventions. Mar 2019, 4281; DOI: 10.1016/j.jcin.2019.01.227. 6. Co-registration tools available within IntraSight 7 configuration via SyncVision. 7. 2018 ESC/EACTS Guidelines on myocardial revascularization: The task force on myocardial revascularization of the European society of cardiology (ESC) and Europeanassociation for cardio-thoracic surgery (EACTS). Eur Heart J. 2018;00:1-96. 8. Patel M, et al., ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 Appropriate Use Criteria for Coronary Revascularization in Patients with Stable Ischemic HeartDisease. J Am Coll Cardiol. 2017 May 2;69(17):2212-2241. 9. ACC CathPCI Hospital Registry. 10. Lofti A, et al. Focused update of expert consensus statement: Use of invasive assessments of coronary physiology and structure: A position statement of the societyof cardiac angiography and interventions. Catheter Cardiovasc Interv. 2018;1–12. 11. Lotfi, A., Davies, J. E., Fearon, W. F., Grines, C. L., Kern, M. J., & Klein, L. W. (2018). Focused update of expert consensus statement: Use of invasive assessments ofcoronary physiology and structure: A position statement of the society of cardiac angiography and interventions. Catheterization and cardiovascular interventions :official journal of the Society for Cardiac Angiography & Interventions, 92(2), 336–347. 12. Witzenbichler B, et al. Relationship between intravascular ultrasound guidance and clinical outcomes after drug-eluting stents: The ADAPT-DES study. Circulation.2014 Jan:129,4;463-470.
How would you improve interventional procedures? What do you think about the new IntraSight Platform? Are we on the right track? Connect with us via #futureofIGT / IntraSight
#futureofIGT, #futureofCAD, #IntraSight, #CoronaryIntervention, #seeclearlytreatoptimally, #IVUS
You are about to visit a Philips global content page
Continue